View in browser

In a study published in Nature Communications, Moores Members Joseph Califano, MD, Robert Saddawi-Konefka, MD, PhD, Andrew Sharabi, MD, PhD, and J. Silvio Gutkind, PhD demonstrate how the timing of two different treatments can improve outcomes for head and neck squamous cell carcinoma.

UC San Diego School of Medicine Associate Professor and Moores Member Raphael Cuomo, PhD has published a study that reveals associations between cannabis use and oral cancer, which paves the way for new methods of cancer screening practices and public health messaging.

In this edition, Ann O’Brien shares her experience with participating in a Moores clinical trial and reflects on the importance of clinical trials in developing and delivering innovative treatments.

Established with the generous support of Schmidt Sciences, a philanthropic initiative of Eric and Wendy Schmidt, this prestigious program annually supports 10-20 Postdoctoral Fellows with a two-year fellowship as they learn and apply AI techniques to their research in the engineering, mathematical, and natural sciences. Applications open on September 1, 2025.

This free, skills-based program is specially designed for health care professionals, medical educators, and researchers. Through interactive sessions, participants will learn how to communicate with greater compassion—and, in turn, greater effectiveness—with patients, health care teams, medical trainees, and beyond.

This Notice of Funding Opportunity will support applied regulatory science research to improve the detection and monitoring of cardiotoxicity of oncology therapeutics. The number of awards will be contingent upon FDA appropriations and the number of meritorious applications. Application budgets must reflect actual proposed project needs and should not exceed $500K/year in total cost (direct and indirect) over 3 years.

Nature Immunology

Debanjan Dhar, PhD (Solid Tumor Therapeutics) and Christopher K. Glass, MD, PhD (Cancer Biology and Signaling)

Blood

Thomas J. Kipps, MD, PhD (Hematologic Malignancies)

Plant Biotechnology Journal

Nicole Steinmetz, PhD (Solid Tumor Therapeutics)

61186372NSC2012: A Phase IIb, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous Amivantamab in Combination with Platinum-Based Chemotherapy as Second-line Treatment, for Common EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

PI: Sandip Patel, MD

NCT ID: NCT06667076

UCSD 811868: Comprehensive Neuroimaging and Molecular Biomarkers of Neurotoxicity Following CAR T-Cell Therapy

PI: Kathryn Tringale, MD, MAS

NCT ID: NCT07075523

22615: A Phase III Open-label, Randomized, Active-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Orally Administered BAY 2927088 Compared with Standard of Care as a Firstline Therapy in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) with HER2activating Mutations

PI: Lyudmila Bazhenova, MD

NCT ID: NCT06452277

TBBO11818-101: A Phase Ia/Ib Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO11818 in Subjects with Advanced KRAS Mutant Cancers

PI: Sandip Patel, MD

NCT ID: NCT06917079

Department of Research Administration

3855 Health Sciences Drive, La Jolla, CA 92037

moorescancercenter.ucsd.edu

Unsubscribe | Privacy Policy | Submit Feedback